Citi added an “upside 30-day catalyst watch” on shares of Apogee Therapeutics (APGE) while keeping a Buy rating on the name with a $95 price target The firm sees a positive risk/reward profile into Apogee’s Phase 2a maintenance study data for zumilokibart in atopic dermatitis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics price target raised to $95 from $90 at Wedbush
- Apogee Therapeutics Stock: Clinical-Stage Risks, Unproven Pipeline, and Uncertain Path to Profitability
- Apogee Therapeutics reports FY25 net loss $255.8M vs. $182.1M last year
- Apogee Therapeutics sees cash runway into 2H28
- Apogee selloff on Sanofi data brings opportunity, says UBS